Enteris Biopharma, Inc.
Records under this name other than the patents Enteris Biopharma, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 6 patents it holds.
Back to Enteris Biopharma, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,513,183 | Peptide Pharmaceutical for Oral Delivery Formerly held In force · High confidence | In force | High confidence | |
| US 9,102,753 | Anti-inflammatory pharmaceutical products Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,072,055 | Anti-inflammatory pharmaceutical products Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 11,998,640 | Room Temperature Stable Oral Calcitonin Formulation Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 7,445,911 | Enzymatic Reactions in the Presence of Keto Acids Term ended Term ended Sep 11, 2026 · High confidence | Term ended | Term ended Sep 11, 2026 | High confidence |
| US 11,285,113 | Room Temperature Stable Oral Calcitonin Formulation Formerly held Lapsed on the fee record Ended Mar 29, 2026 · High confidence | Lapsed on the fee record | Ended Mar 29, 2026 | High confidence |
| US 8,664,178 | Peptide Pharmaceutical for Oral Delivery Formerly held Lapsed on the fee record Ended Mar 4, 2026 · Medium confidence | Lapsed on the fee record | Ended Mar 4, 2026 | Medium confidence |
| US 9,833,411 | Solid Oral Dosage Forms Lapsed on the fee record Ended Dec 5, 2025 · High confidence | Lapsed on the fee record | Ended Dec 5, 2025 | High confidence |
| US 8,592,366 | Peptide Pharmaceutical for Oral Delivery Formerly held Lapsed on the fee record Ended Nov 26, 2025 · Medium confidence | Lapsed on the fee record | Ended Nov 26, 2025 | Medium confidence |
| US 9,504,727 | Oral Delivery of Peptide Pharmaceutical Compositions Lapsed on the fee record Ended Nov 29, 2024 · Low confidence | Lapsed on the fee record | Ended Nov 29, 2024 | Low confidence |